Histone deacetylase inhibitors in multiple myeloma

Sarah Deleu, Eline Menu, Els Van Valckenborgh, Ben Van Camp, Joanna Fraczek, Isabelle Vande Broek, Vera Rogiers, Karin Vanderkerken
  • Sarah Deleu
    Affiliation not present
  • Eline Menu
    Affiliation not present
  • Els Van Valckenborgh
    Affiliation not present
  • Ben Van Camp
    Affiliation not present
  • Joanna Fraczek
    Affiliation not present
  • Isabelle Vande Broek
    Affiliation not present
  • Vera Rogiers
    Affiliation not present


Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.

Full Text:

Submitted: 2009-02-09 11:31:04
Published: 2009-06-03 20:56:40
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c)
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy